{"filings":[{"id":1609598,"accession_number":"0001193125-26-301997","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-07-13T20:01:13+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Galera Therapeutics effects 1-for-200 reverse stock split; shares to trade under GRTXD on OTCQB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock at 1:200 ratio effective July 12, 2026.","No fractional shares; stockholders receive cash value based on closing price prior to split.","Outstanding options and warrants adjusted proportionally with exercise price increases.","Common stock begins trading on OTCQB under ticker GRTXD on July 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1481596,"accession_number":"0001193125-26-296981","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-07-07T12:49:56+00:00","items":["8.01"],"status":"ready","headline":"Galera Therapeutics announces 1-for-200 reverse stock split effective July 12, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:200 ratio; effective July 12, 2026 at 11:59 p.m. ET.","Split-adjusted trading begins at market open on July 13, 2026 on OTCQB.","No fractional shares; stockholders receive cash value based on closing price prior to effective date.","Proportionate adjustments to shares available under equity plans and outstanding options/warrants.","Exercise prices of options and warrants will be increased accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526559,"accession_number":"0001193125-26-230711","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-05-19T20:01:45+00:00","items":["8.01"],"status":"ready","headline":"Galera Therapeutics converts all Series B Preferred Stock into 42.8M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted 42,839.11 Series B preferred shares into 42,839,103 common shares on May 15, 2026.","No fractional shares were issued; holders will receive cash in lieu of fractional shares.","After conversion, no shares of Series B Preferred Stock remain outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":451996,"accession_number":"0001193125-26-225174","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-05-15T10:30:06+00:00","items":["5.03","9.01"],"status":"ready","headline":"Galera Therapeutics doubles authorized common stock to 400M shares; adds written consent right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 200M to 400M shares via charter amendment filed May 11, 2026.","Stockholders approved the stock increase and written consent right at May 8, 2026 annual meeting.","Written consent charter amendment and amended bylaws filed May 12, enabling stockholder action by written consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12764,"accession_number":"0001193125-26-216710","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-05-11T20:02:33+00:00","items":["5.07"],"status":"ready","headline":"Galera shareholders approve reverse split (1:75 to 1:200) and share increase to 400M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected J. Mel Sorensen (Class III), Nancy Chang and Michael Friedman (Class I) as directors.","Ratified KPMG as auditor for FY 2026.","Approved say-on-pay and annual frequency for future say-on-pay votes.","Authorized amendment raising common shares from 200M to 400M.","Authorized reverse stock split at Board-discretion ratio between 1:75 and 1:200."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93671,"accession_number":"0001193125-26-154009","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","3.02","5.01","7.01","9.01"],"status":"ready","headline":"Galera Therapeutics to merge with Obsidian in all-stock deal backed by $350M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Galera and Obsidian to merge under new parent; Galera shareholders get ~1.8% of combined co plus CVRs.","Obsidian shareholders get ~53.2%; $350M PIPE investors get ~45% of combined company.","Galera valued at $13.8M (net cash $1.8M), Obsidian at $413.5M; closing conditions include S-4 effectiveness.","Galera legacy assets (tilarganine, avasopasem, rucosopasem) subject to CVR payout to Galera common holders.","Insider support: 51.1% Galera holders and 62.8% Obsidian holders agree to vote in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93670,"accession_number":"0001193125-26-149590","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galera converts 76.5K Series B preferred into 76.5M common shares; warrants exercised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted 76,479.175 Series B Preferred shares into 76,479,164 common shares on April 7, 2026.","After conversion, 42,839.11 Series B Preferred shares remain outstanding.","Ikarian Capital affiliates exercised pre-funded warrants for 8,488,229 common shares at $0.001/share on April 8, 2026.","Remaining pre-funded warrants to purchase 14,552,811 common shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93669,"accession_number":"0001193125-26-141187","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galera Therapeutics schedules 2025/2026 Annual Meeting for May 8, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholder proposal/nomination deadline set for April 13, 2026.","Meeting date is more than 60 days after 2024 Annual Meeting; new deadlines apply.","Universal proxy rule (Rule 14a-19) notice also due by April 13, 2026.","Proposals for inclusion in proxy materials must be received by April 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105491,"accession_number":"0001193125-26-055919","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Galera Therapeutics amends Series B Preferred terms to allow board discretion to convert to common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Feb 12, 2026, Galera filed a Certificate of Amendment to its Series B Preferred Certificate of Designation.","Amendment grants the board sole discretion to convert Series B Preferred into common stock using the Conversion Ratio.","Amendment was approved by the board and by unanimous written consent of Series B holders.","No immediate conversion; board may elect to convert in whole or in part at a later date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105490,"accession_number":"0001193125-26-048696","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Galera Therapeutics enters retention bonus agreement with CAO Joel Sussman for up to $250,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $250,000 in retention bonuses tied to timely completion and filing of reporting obligations.","Retention payments reduce severance payments under existing employment agreement dollar-for-dollar.","Unpaid bonus accelerates if involuntary termination (not for cause) or good reason occurs.","Agreement dated February 6, 2026, with payments tied to specific conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121768,"accession_number":"0001193125-25-250698","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Galera Therapeutics sells avasopasem and rucosopasem assets to Biossil Inc.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold all dismutase mimetic assets including avasopasem (GC4419) and rucosopasem (GC4711) to Biossil Inc., a Canadian company.","Transaction closed Oct 15, 2025; Blackstone Agreement assigned to Biossil on Oct 21, 2025.","Blackstone will look solely to Biossil for all obligations under the Amended Blackstone Agreement; Galera relieved of those liabilities.","No purchase price or deal financial terms disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121767,"accession_number":"0001193125-25-245093","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Galera sells avasopasem/rucosopasem assets to Biossil for $3.5M upfront, up to $105M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Biossil Inc. acquires all of Galera's dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711).","Upfront payment of $3,500,000; potential regulatory/commercial milestones and contingent value rights total up to $105,000,000.","Biossil assumes rights and obligations under the 2018 Clarus IV Galera Royalty agreement (affiliated with Blackstone Life Sciences).","Purchase Agreement contains customary representations, warranties, and covenants; filing of full agreement will follow in next Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138439,"accession_number":"0001193125-25-194948","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Galera Therapeutics reduces Blackstone royalty to 4% from high single-digit on halted products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment cuts royalty payable to Blackstone on worldwide net sales of avasopasem/rucosopasem from high single-digit % to 4%.","Reduced rate also applies to Product Payment damages received during the royalty period.","Company has suspended clinical development and commercial readiness for both products.","Purchaser is Blackstone Life Sciences, successor in interest to Clarus Ventures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155900,"accession_number":"0001193125-25-071428","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Galera extends registration statement filing deadline to June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Registration Rights Agreement dated Dec 30, 2024 extends Filing Deadline by 180 days from Closing Date.","New deadline to file initial registration statement is June 30, 2025.","Amendment entered into with purchasers from December 2024 securities purchase agreement.","No other material terms of the Registration Rights Agreement were modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174355,"accession_number":"0001193125-25-060802","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K/A","filed_at":"2025-03-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Galera completes acquisition of Nova Pharmaceuticals, files 8-K/A with SEC waiver for financial statements","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Acquisition of Nova Pharmaceuticals closed on Dec 30, 2024, via merger agreement.","SEC granted waiver from Rule 3-05 and Article 11, allowing omission of audited FY2023 and unaudited interim financials for 9 months ended Sep 30, 2023/2024.","Pro forma financial information also omitted under the waiver.","No deal value or terms disclosed in this filing; full financial impact not provided to investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174356,"accession_number":"0001193125-25-035114","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galera Therapeutics stockholders elect two Class II directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lawrence Alleva elected with 27,501,778 votes for, 3,359,405 withheld, 10,682,973 broker non-votes.","Kevin Lokay elected with 27,504,038 votes for, 3,357,145 withheld, 10,682,973 broker non-votes.","KPMG LLP ratified as independent auditor for FY2024 with 41,342,291 for, 184,580 against, 17,285 abstentions.","Annual meeting held on February 24, 2025; all proposals approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.04,"calibrated_materiality_score":0.04,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191306,"accession_number":"0001193125-24-287073","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","9.01"],"status":"ready","headline":"Galera Therapeutics acquires Nova Pharmaceuticals in merger; issues Series B Preferred and closes $2.885M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 30; Galera issued 119,318 shares of Series B Non-Voting Convertible Preferred (1,000-to-1 conversion).","Raised $2.885M via private placement of 44,111,260 common shares and pre-funded warrants.","Three directors resigned (Powell, West, Cunningham); Nancy Chang and Michael Friedman appointed as Class I directors.","Board reduced from six to five; stockholders to vote on Series B conversion and reverse split within 12-18 months.","90-day lock-up on shares from merger for certain securityholders and directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191305,"accession_number":"0001193125-24-283187","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galera Therapeutics schedules 2024 annual meeting for Feb 24, 2025; sets proposal deadline Dec 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting set for February 24, 2025; deadline for stockholder proposals and director nominations is December 30, 2024.","Stockholders must comply with bylaw informational requirements; notice to secretary Joel Sussman at Malvern, PA address.","Universal proxy rule compliance requires additional notice for solicitations in support of non-company nominees by same deadline (Dec 30).","Proposals for inclusion in proxy materials under Rule 14a-8 must be received by Dec 30 to be considered timely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191304,"accession_number":"0001193125-24-239251","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galera Therapeutics shareholders reject liquidation and dissolution plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to approve dissolution received 13,938,893 FOR and 18,075,579 AGAINST; not approved.","Proposal to adjourn for additional proxy solicitation also failed: 14,036,711 FOR vs 17,977,422 AGAINST.","Company has discontinued business activities and lacks resources; board to explore alternatives.","Special meeting held October 17, 2024; 32,061,280 shares (58.94% of outstanding) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207787,"accession_number":"0001193125-24-212627","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera Therapeutics gets Nasdaq delisting notice; stock to be delisted mid-September","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Galera on Aug 31, 2024; will file Form 25 on Sept 4 to delist common stock.","Trading on Nasdaq Global Market was suspended since June 4, 2024 for non-compliance.","Stock currently quoted on OTC Pink Market under symbol GRTX.","Non-compliance with minimum market value, bid price, and publicly held shares triggered delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207786,"accession_number":"0001193125-24-200220","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Galera Therapeutics board approves dissolution; CFO and CLO positions eliminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously approved Plan of Liquidation and Dissolution; special stockholder meeting on or around Oct 17, 2024.","Workforce reduced to 3 employees; CFO Chris Degnan and CLO Jennifer Evans Stacey positions cut effective Aug 31, 2024.","Q2 2024 net loss $4.1M ($0.07 per share) vs $20.7M ($0.48) in Q2 2023; R&D expenses fell to $1.4M.","Cash and equivalents $10.7M as of June 30, 2024; expects to fund dissolution costs for at least 12 months.","No suitable strategic alternatives found; may still sell pipeline assets, proceeds to be distributed to stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207785,"accession_number":"0001193125-24-196457","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Galera settles Phase 3 ROMAN trial CRO lawsuit for $975,000","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Alira Health Clinical and IQVIA Biotech resolves breach-of-contract and negligence claims.","CROs paid $975,000 in exchange for mutual releases and termination of contracts with no further obligations.","Lawsuit stemmed from a 2021 error in statistical programming for the Phase 3 ROMAN trial of avasopasem.","Galera expects to file a Praecipe to end the litigation by August 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225264,"accession_number":"0001193125-24-156660","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Galera Therapeutics eliminates COO role; stock moves to OTC Pink","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Robert Beardsley's position eliminated June 4, 2024 to reduce costs.","Company continues comprehensive review of strategic alternatives.","Beardsley eligible for severance; expects consulting at ~$400/hour.","Common stock now quoted on OTC Pink (GRTX); Nasdaq trading suspended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225263,"accession_number":"0001193125-24-152343","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera Therapeutics receives Nasdaq delisting notice; trading to suspend June 4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice from Nasdaq on May 31, 2024 for failure to meet minimum market value, bid price, and publicly held shares requirements.","Nasdaq will suspend trading of common stock (GRTX) at open on June 4, 2024.","Company expects common stock to be quoted on OTC Markets under symbol GRTX.","Company has the right to request a review of the Nasdaq Hearings Panel's decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225262,"accession_number":"0001193125-24-136687","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera Q1 net loss narrows to $4.4M; ceases clinical development, explores strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($0.08/sh) vs $17.7M ($0.50/sh) in Q1 2023; R&D expenses fell to $1.5M.","Cash and equivalents $13.5M as of March 31, 2024; expected to fund operations into Q3 2025.","Company ceased all clinical trial activity and suspended clinical development of avasopasem and rucosopasem.","Board adopted stockholder rights agreement on May 3, 2024 in response to recent stock accumulations.","Evaluating strategic alternatives with Stifel; options may include mergers, asset sales, or dissolution."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225261,"accession_number":"0001193125-24-130779","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Galera Therapeutics adopts limited-duration poison pill after recent stock accumulations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Rights Agreement effective May 2, 2024, responding to recent accumulations of common stock.","Each outstanding common share receives one right; triggers at 10% beneficial ownership without Board approval.","Upon trigger, rights holders (except acquirer) can buy shares at 50% discount; rights expire May 2, 2025.","Record date for dividend of rights is May 20, 2024; exercise price $1.50 per right."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244468,"accession_number":"0001193125-24-079600","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera reports FY2023 net loss $59.1M; avasopasem NDA rejected; strategic review may lead to dissolution","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss $59.1M ($1.33/sh); Q4 net loss $5.6M ($0.10/sh); cash $18.3M as of Dec 31, 2023.","Cash and equivalents $18.3M at year-end; expected to fund operations into Q2 2025.","FDA issued CRL for avasopasem NDA in Aug 2023; requires additional Phase 3 trial for resubmission.","Halted GRECO-2 (pancreatic) and GRECO-1 (NSCLC) trials after futility; workforce reduced 70% in Aug 2023.","Engaged Stifel to review strategic alternatives; CEO notes process could lead to dissolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244467,"accession_number":"0001193125-24-078226","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera Therapeutics receives Nasdaq delisting notices; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["March 21 notice: failed to meet $50M MVLS and $1.00 bid price for 30 consecutive days.","March 26 notice: failed to meet $15M market value of publicly held shares requirement.","Company will request hearings by March 28 and April 2 deadlines; stay pending outcome.","May request transfer to Nasdaq Capital Market; no guarantee of approval or continued listing.","Common stock (GRTX) expected to remain listed at least until Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261915,"accession_number":"0001193125-23-276640","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera Therapeutics reports Q3 loss; FDA requires new avasopasem trial; GRECO trials halted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA issued Complete Response Letter for avasopasem NDA; requires an additional Phase 3 trial for resubmission.","GRECO-2 (pancreatic cancer) and GRECO-1 (NSCLC) trials halted following futility analyses.","Workforce reduced by 22 employees (~70%) in August 2023; restructuring charges of $2.3M in Q3.","Q3 2023 net loss of $15.1M ($0.33 per share) vs. $16.0M ($0.60) in Q3 2022; cash $28.4M.","Company exploring strategic alternatives including mergers, asset sales; may be required to cease operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261914,"accession_number":"0001193125-23-266704","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Galera: FDA demands new Phase 3 for avasopasem; GRECO-2 futility halts both rucosopasem trials","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA reiterated need for an additional Phase 3 trial of avasopasem for radiotherapy-induced SOM.","GRECO-2 futility analysis (35 deaths, 177 enrolled) led to discontinuation of both GRECO-1 and GRECO-2 trials.","Preliminary cash, cash equivalents & short-term investments: $28.4M as of Sep 30, 2023.","Engaged Stifel to review strategic alternatives (merger, sale, licensing); may cease operations if none found.","Company assessing strategic options to maximize shareholder value; going concern risk noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279087,"accession_number":"0001193125-23-241844","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera Therapeutics receives Nasdaq delisting notice for MVPHS non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Galera on Sep 25, 2023 that MVPHS fell below $15M required for Global Market listing.","Company has 180 days, until March 25, 2024, to regain compliance by closing at $15M+ for 10 consecutive days.","May consider transferring to Nasdaq Capital Market if compliance cannot be met on Global Market.","Stock continues to trade under GRTX on Nasdaq Global Market; delisting risk if not cured by Compliance Date.","No assurance that compliance will be regained or that an appeal would succeed if delisting proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279086,"accession_number":"0001193125-23-240624","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera Therapeutics receives Nasdaq delisting notices for MVLS and bid price deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notices: MVLS below $50M and bid price below $1.00 for 30 consecutive business days.","Compliance deadline is March 20, 2024; 180-day cure period for both requirements.","If not compliant, faces delisting; may appeal or transfer to Nasdaq Capital Market.","Company will monitor and consider options but cannot assure compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279085,"accession_number":"0001193125-23-211441","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera receives FDA CRL for avasopasem, cuts workforce 70%, Q2 net loss $20.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA issued Complete Response Letter for avasopasem NDA; additional clinical trial required for resubmission.","Company reduced workforce by ~70% to extend cash runway into Q2 2024.","Q2 net loss $(20.7)M, $(0.48) per share; R&D $7.6M, G&A $9.2M.","Cash, equivalents and investments $38.8M as of June 30, 2023.","Orphan drug designation for rucosopasem in pancreatic cancer; GRECO trials enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279084,"accession_number":"0001193125-23-208137","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Galera Therapeutics receives FDA CRL for avasopasem; cuts workforce by 70% to extend cash runway","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued CRL for avasopasem NDA; Phase 3 ROMAN + GT-201 data not sufficiently persuasive; additional trial required.","Workforce reduced by 22 employees (~70%); estimated restructuring charges of $2.0M to $2.5M.","Preliminary cash, equivalents, and short-term investments of $38.8M as of June 30, 2023; cash runway extended into Q2 2024.","Mark Bachleda, Chief Commercial Officer, position eliminated in workforce reduction.","Company intends to request Type A FDA meeting and explore strategic alternatives including partnering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297419,"accession_number":"0001193125-23-167905","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galera Therapeutics shareholders elect two Class I directors, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Powell, Ph.D. elected with 15,141,283 votes for (76.2% of votes cast).","Linda West elected with 15,219,991 votes for (76.6% of votes cast); broker non-votes were 8,447,493.","KPMG LLP ratified as independent auditor for 2023 with 28,291,469 votes for, 9,547 against.","Turnout was 28,312,177 shares, representing 65.98% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297418,"accession_number":"0001193125-23-156074","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galera Therapeutics sues CROs over Phase 3 ROMAN trial statistical error","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed lawsuit in Pennsylvania against Alira Health Clinical and IQVIA Biotech for breach of contract and negligence.","Error in 2021 statistical program for Phase 3 ROMAN trial corrected; yielded statistically significant p-values for primary and key secondary endpoints.","Litigation is in early stages; company cannot predict outcome at this time.","FDA accepted NDA for avasopasem with Priority Review; PDUFA target date August 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297417,"accession_number":"0001193125-23-141380","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera Therapeutics Q1 net loss $17.7M; avasopasem NDA gets FDA priority review with PDUFA Aug 9","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M ($0.50 per share) in Q1 2023 vs $15.4M ($0.58 per share) in Q1 2022.","Cash, cash equivalents and short-term investments of $47.8M as of March 31, 2023; expected to fund operations into Q4 2023.","FDA granted priority review for avasopasem NDA for radiotherapy-induced severe oral mucositis; PDUFA date August 9, 2023.","Raised $30M gross proceeds from registered direct offering in February 2023.","Expanded commercial leadership team with three new VPs in preparation for potential U.S. launch."],"consensus_eps_estimate":-0.3899,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317765,"accession_number":"0001193125-23-067663","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Galera Therapeutics discloses no exposure to Silicon Valley Bank failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms it holds no cash deposits or securities with SVB.","No business relationship of any kind exists with Silicon Valley Bank.","Disclosure follows SVB closure by California regulator and FDIC receivership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317764,"accession_number":"0001193125-23-063736","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera reports FY2022 net loss $62.2M; avasopasem NDA priority review, PDUFA Aug 9, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss of $16.2M ($0.58 per share); FY2022 net loss $62.2M ($2.30 per share).","Cash, cash equivalents and short-term investments $31.6M as of Dec 31, 2022; raised $30M in Feb 2023 offering.","NDA for avasopasem (radiotherapy-induced severe oral mucositis) granted FDA priority review; PDUFA date August 9, 2023.","No FDA-approved drug currently exists for SOM in head and neck cancer patients; ~43,500 US patients at high risk annually.","Enrollment ongoing in Phase 2b GRECO-2 (LAPC) and GRECO-1 (NSCLC) trials of rucosopasem; completion expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317763,"accession_number":"0001193125-23-041168","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Galera raises $30M in registered direct offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 14,320,000 shares at $2.095/share plus warrants to buy 14,320,000 shares at $1.97.","Gross proceeds of $30M; net to fund avasopasem pre-commercialization, rucosopasem development, and working capital.","Closing expected February 17, 2023; 90-day lock-up for officers and directors.","Piper Sandler acted as sole placement agent; 6% placement fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317762,"accession_number":"0001193125-23-039798","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Galera Therapeutics announces FDA priority review of NDA for avasopasem in SOM; PDUFA date Aug 9, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for avasopasem manganese for radiotherapy-induced severe oral mucositis in head/neck cancer.","Priority review assigned; PDUFA target action date of August 9, 2023; no advisory committee meeting planned.","Company estimates total US market opportunity for SOM exceeds $1 billion.","Preliminary cash and investments balance of ~$31.6M as of Dec 31, 2022; audited results pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317761,"accession_number":"0001193125-23-015157","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galera Therapeutics regains compliance with Nasdaq MVLS requirement, delisting avoided","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with $50M MVLS requirement for continued listing on Nasdaq Global Market.","Hearing before Nasdaq Hearings Panel on Jan 26, 2023 cancelled.","Company had previously been notified of non-compliance in Dec 2022 and appealed delisting.","Common stock (GRTX) will continue trading on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336025,"accession_number":"0001193125-22-302295","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galera submits NDA for avasopasem to reduce severe oral mucositis in head & neck cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDA for avasopasem submitted to FDA for radiotherapy-induced severe oral mucositis (SOM) in head/neck cancer.","Two positive placebo-controlled trials (Phase 3 ROMAN, Phase 2b GT-201) enrolled 678 patients total.","ROMAN trial: statistically significant reduction in SOM incidence; median SOM days more than halved vs placebo.","Prospectively defined analysis showed avasopasem reduced cisplatin-related chronic kidney disease by 50%.","FDA previously granted Fast Track and Breakthrough Therapy designations; no approved SOM drug currently exists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336024,"accession_number":"0001193125-22-301791","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera receives Nasdaq delisting notice for failing to meet $50M MVLS; plans appeal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Galera on Dec 6, 2022 of failure to regain compliance with $50M MVLS requirement by Dec 5 deadline.","Trading suspension and delisting from Nasdaq Global Market scheduled for Dec 15 unless hearing requested by Dec 13.","Company will request a hearing to appeal; request will stay suspension pending Panel decision.","May seek transfer to Nasdaq Capital Market if Global Market listing is not continued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336023,"accession_number":"0001193125-22-280669","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera reports Q3 net loss $16M; avasopasem NDA on track by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16M ($0.60/share) vs $22.6M ($0.86) in Q3 2021; cash $42.8M.","NDA for avasopasem in radiotherapy-induced severe oral mucositis remains on track for submission by end of 2022.","One-year ROMAN follow-up showed tumor outcomes and overall survival maintained; 50% reduction in chronic kidney disease (10% vs 20% placebo, p=0.0043).","Meta-analysis of ROMAN and GT-201 (n=551) showed reductions in SOM incidence, duration, onset, and severity.","Appointed Eugene P. Kennedy, M.D., as Chief Medical Officer, succeeding Jon T. Holmlund who plans to retire."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336022,"accession_number":"0001193125-22-269333","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Galera presents positive Phase 3 ROMAN one-year data; meta-analysis confirms SOM reduction; NDA on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-year follow-up: avasopasem maintained comparable tumor outcomes and overall survival vs placebo in HNC patients.","CKD incidence 10% (avasopasem) vs 20% (placebo) at one year (p=0.0043), a 50% reduction.","Meta-analysis (n=551): avasopasem reduced SOM incidence by 19% (p=0.0053) and median days of SOM by 58% (p=0.0002).","Meta-analysis also showed 28% delay in SOM onset (p=0.0005) and 32% reduction in Grade 4 incidence (p=0.0102).","NDA submission for avasopasem for radiotherapy-induced SOM still on track for end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353431,"accession_number":"0001193125-22-215574","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera reports Q2 net loss $14.6M ($0.54/sh); NDA for avasopasem on track by end of 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M ($0.54 per share) in Q2 2022, compared to $22.4M ($0.88/sh) in Q2 2021.","R&D expenses $6.7M (down from $16.0M YoY); cash and investments $52.0M as of June 30, 2022.","Phase 3 ROMAN data: avasopasem reduced SOM incidence and days; NDA submission on track for end of 2022.","Phase 1 GRECO-1: rucosopasem+SBRT showed 6/7 patients with partial response or stable disease; Phase 2 enrollment completion expected 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371159,"accession_number":"0001193125-22-175514","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galera Therapeutics stockholders elect two Class III directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Emmett Cunningham and Dr. J. Mel Sorensen elected as Class III directors with ~10.6M and ~10.7M votes for, respectively.","KPMG LLP ratified as independent auditor for FY2022 with 17,167,149 votes for, 46,053 against, and 9,939 abstained.","Approximately 64.21% of outstanding shares (17,223,141) were present or represented at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371158,"accession_number":"0001193125-22-171970","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galera Therapeutics receives Nasdaq delisting notice for failure to meet $50M MVLS requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 8, 2022 for non-compliance with minimum Market Value of Listed Securities of $50M.","Has 180 days, until December 5, 2022, to regain compliance by closing at $50M+ for 10 consecutive business days.","Stock continues trading on Nasdaq Global Market under symbol GRTX; may consider transfer to Nasdaq Capital Market.","No assurance of regaining compliance; failure may lead to delisting subject to appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371157,"accession_number":"0001193125-22-150894","cik":1563577,"company_name":"Galera Therapeutics, Inc.","ticker":"GRTX","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Galera Q1 net loss $15.4M; plans avasopasem NDA by end 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(15.4M) ($0.58/share) vs $(18.7M) ($0.75) in Q1 2021; cash $60.9M funds into H2 2023.","Plans to submit NDA for avasopasem for severe oral mucositis by end of 2022 after FDA discussions.","Phase 3 ROMAN data accepted for oral presentation at 2022 ASCO; positive Phase 2a AESOP data reported.","R&D expenses $8.1M (down from $12.4M); G&A expenses $5.0M (flat).","Enrollment ongoing in Phase 2b GRECO-2 trial of rucosopasem for pancreatic cancer and Phase 1/2 GRECO-1 for NSCLC."],"consensus_eps_estimate":-0.3899,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16823940.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-16T23:59:59+00:00|371157"}